Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CANbridge Life Sciences
Biotech
CANbridge posts early-phase data on rival to AstraZeneca drug
With access to Soliris and Ultomiris limited in parts of the world, CANbridge has taken a rival C5 inhibitor through a phase 1 study.
Nick Paul Taylor
Feb 7, 2022 8:35am
After surprise FDA win, Aveo reverts to normal as partner splits
Mar 15, 2021 8:55am
Novartis nabs GSK exec for Sandoz CEO—Chutes & Ladders
Apr 26, 2019 9:30am
WuXi teams with CANbridge Pharma on rare disease therapies
Oct 24, 2018 1:23pm
Chutes & Ladders—Cell Medica names Kite's European chief as CEO
Aug 3, 2018 9:43am
Beijing’s CANbridge brings on Pfizer rare disease leader as CMO
Jul 31, 2018 9:31am
